LIFE SCIENCE WASHINGTON INSTITUTE

FUNDING OPPORTUNITY!

SEEKING TOOLS TO COMBAT COVID-19

The Office of Biomedical Advanced Research and Development Authority (BARDA) is supporting the U.S. Government to identify medical countermeasures with the potential to help address the COVID-19 outbreak. Read about current partnerships at bit.ly/BARDApartnerships



If your company is developing **therapeutics, vaccines, or other products (e.g. software platforms, wearable technologies, personal protective equipment, etc.)** that could help combat the COVID-19 pandemic, see the next page for potential opportunities for partnership and funding!

What are BARDA & DRIVe?

In 2019, the Biomedical Advanced Research and Development Authority (BARDA) expanded their Division of Research, Innovation, and Ventures (DRIVe). DRIVe provides technical and financial resources to entrepreneurs whose ideas have the potential to transform emergency preparedness, detection, and response.

LSWI is one of 13 sites in the DRIVe accelerator network to connect innovators with government resources. To date, **54 BARDA-supported products have achieved regulatory approval, licensure or clearance.** For more on DRIVe, visit drive.hhs.gov.

DRIVe Transforming Health Security

LIFE SCIENCE WASHINGTON INSTITUTE

FUNDING OPPORTUNITY!

PATHWAYS FOR POTENTIAL FUNDING:

BARDA BAA

BARDA is investing in an array of medical countermeasures to diagnose, treat, or protect against the 2019 novel coronavirus under the BARDA Broad Agency Announcement (BAA-18-100-SOL-00003). Specifically, BARDA is pursuing the following products or technologies:

- Diagnostic assays for human pan-coronaviruses
- Vaccines for novel coronavirus
- Therapeutics for novel coronavirus
- Ventilators
- Immunomodulators or therapeutics targeting lung repair
- Pre-exposure and post-exposure prophylaxis for novel coronavirus exposure
- Respiratory protective devices

To learn more, including targets for product maturity under this announcement, see the newly revised BARDA Broad Agency Announcement.

DRIVe EZ-BAA

To spur innovation, BARDA has issued its business-friendly, streamlined Easy Broad Agency Announcement (EZ-BAA) for **molecular diagnostics** and **nonclinical assays.**

The diagnostics must leverage FDA-cleared platforms and have a viable plan to meet requirements for the FDA to consider Emergency Use Authorization within 12 weeks of an award.

To learn more, see the Novel Coronavirus EZ-BAA.

FEDERAL MARKET RESEARCH

If you are interested in partnering with the federal government on a COVID-19 medical countermeasure, submit your ideas to a platform that reaches a host of potential federal partners! Submit a brief description and supporting materials through the Market Research Initiative.

Contact Laura Sconyers laura@lswinstitute.org for more info!